The New York Times Company reports strong Q2 2025 results, with digital revenue and subscriptions rising, despite a slowdown in new additions.
Bio-Techne's earnings beat overshadowed by concerns over tariffs, funding cuts, and drug pricing reforms, leading to a stock drop despite strong performance in key units.
Wildfire deaths in LA far exceed official count, highlighting the urgent need for improved disaster mortality tracking and research into long-term health impacts.
The New York Times Company reports strong Q2 2025 results, with digital revenue and subscriptions rising, despite a slowdown in new additions.
Bio-Techne's earnings beat overshadowed by concerns over tariffs, funding cuts, and drug pricing reforms, leading to a stock drop despite strong performance in key units.
Wildfire deaths in LA far exceed official count, highlighting the urgent need for improved disaster mortality tracking and research into long-term health impacts.